Department of Medicine, Nepean Hospital, Kingswood, New South Wales, Australia.
The University of Sydney Nepean Clinical School, Kingswood, New South Wales, Australia.
BMJ Case Rep. 2024 Jul 11;17(7):e259875. doi: 10.1136/bcr-2024-259875.
Systemic capillary leak syndrome (SCLS) is a rare and life-threatening disorder characterised by leaking of intravascular fluid to extravascular tissues. An association with immunotherapy and COVID-19 vaccination has been reported as potential triggers. A case of a patient in her 70s developing SCLS after the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccination with a history of metastatic melanoma treated with nivolumab (PD-1 monoclonal antibody) and ipilimumab (anti-CTLA4 monoclonal antibody) is reported. The aetiology and management of SCLS are also reviewed in this case context.
全身性毛细血管渗漏综合征（SCLS）是一种罕见且危及生命的疾病，其特征是血管内液体渗漏到血管外组织。据报道，免疫治疗和 COVID-19 疫苗接种与之相关，可能是其潜在诱因。本文报告了一例 70 多岁的转移性黑色素瘤患者在接受 BNT162b2（辉瑞-生物科技）COVID-19 疫苗接种后发生 SCLS 的病例，该患者曾接受过纳武单抗（PD-1 单克隆抗体）和伊匹单抗（抗 CTLA4 单克隆抗体）治疗。本文还结合该病例讨论了 SCLS 的病因和治疗方法。
